Related references
Note: Only part of the references are listed.IL-8 associates with a pro-angiogenic and mesenchymal subtype in glioblastoma
Siobhan Conroy et al.
Oncotarget (2018)
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer
Charli Dominguez et al.
JCI INSIGHT (2017)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients
M. F. Sanmamed et al.
ANNALS OF ONCOLOGY (2017)
The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance
Justin M. David et al.
VACCINES (2016)
Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Miguel F. Sanmamed et al.
CLINICAL CANCER RESEARCH (2014)
Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis
Claudia Palena et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
Steven L. Highfill et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype
Cecilia Larocca et al.
MOLECULAR CANCER THERAPEUTICS (2013)
The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies
B. Huang et al.
CELL DEATH & DISEASE (2013)
Brachyury, a Driver of the Epithelial-Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Mario Roselli et al.
CLINICAL CANCER RESEARCH (2012)
Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment
Claudia Palena et al.
FUTURE ONCOLOGY (2012)
Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Nannie Bangsgaard et al.
PLOS ONE (2012)
Cancer Vaccines Targeting the Epithelial-Mesenchymal Transition: Tissue Distribution of Brachyury and Other Drivers of the Mesenchymal-Like Phenotype of Carcinomas
Duane H. Hamilton et al.
SEMINARS IN ONCOLOGY (2012)
IL-8 Signaling Plays a Critical Role in the Epithelial-Mesenchymal Transition of Human Carcinoma Cells
Romaine I. Fernando et al.
CANCER RESEARCH (2011)
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models
Yan Ning et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Breast Cancer Cell Lines Contain Functional Cancer Stem Cells with Metastatic Capacity and a Distinct Molecular Signature
Emmanuelle Charafe-Jauffret et al.
CANCER RESEARCH (2009)
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression
Chiara Gabellini et al.
EUROPEAN JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation
Angela Seaton et al.
CARCINOGENESIS (2008)
The Interleukin-8 Pathway in Cancer
David J. J. Waugh et al.
CLINICAL CANCER RESEARCH (2008)
IL-8 as antibody therapeutic target in inflammatory diseases: Reduction of clinical activity in palmoplantar pustulosis
Lone Skov et al.
JOURNAL OF IMMUNOLOGY (2008)
HIF-1 and NF-κB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells
P. J. Maxwell et al.
ONCOGENE (2007)
The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis
DJ Brat et al.
NEURO-ONCOLOGY (2005)
IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells
A Freund et al.
ONCOGENE (2003)
Interleukin-8 and human cancer biology
KP Xie
CYTOKINE & GROWTH FACTOR REVIEWS (2001)
Share Paper
